Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk

Completed

• Conditions: Erectile Dysfunction

• Registration Number: NCT00874185
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

Evaluate satisfaction in people treated with IPDE5 inhibitors over time

Detailed Description

12 first patients that are eligible

Study Timeline

• Study Start: 2007-12
• Primary Completion: 2008-05
• Study Completion: 2008-05
• Study First Submitted: 2009-04-01
• Study First Submitted QC: 2009-04-01
• Study First Posted: 2009-04-02
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-28
• Last Update Posted: 2021-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 720

Inclusion Criteria

• CV risk factors
• Male above 18

Exclusion Criteria

• Non-informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
EDITS	6 months
SEAR	6 months

Secondary Outcome Measures

Name	Time	Method
Medication prescribed	6 months